Solventum beats Q2 estimates, raises 2026 outlook

EarningsCorporate Action

โดย Zacks Investment Research·

Summary · why it matters

Solventum reported second-quarter 2026 adjusted earnings per share of $2.55, beating the Zacks Consensus Estimate of $1.91 by 33.5% and improving 50.9% year over year. Revenues of $2.21 billion rose 2.2% and surpassed the consensus mark of $2.17 billion by 2%, with organic sales increasing 9.5% aided by advance orders ahead of ERP cutovers. The company raised its 2026 adjusted earnings guidance to $7.10 to $7.20 per share from the prior range of $6.40 to $6.60 and lifted the lower end of its organic sales growth outlook to 2.5% to 3%. Solventum also announced plans to separate its Health Information Systems business to sharpen its MedTech focus. Shares gained 2.9% in after-market trading following the results.

Solventum Corp. ▲